- Intended Audience: Pharmacists interested in pharmacogenomics.
- Universal Activity Number: 0012-0000-22-039-H01-P
- Contact Hours: 26.0 hours of ACPE continuing education for pharmacists
- Program Fees: $499.00
- Dates Available: 10/21/2022 – 10/21/2025
- Activity Type: Practice/Certificate Program
- Program Support: No outside financial support was provided.
- Format Type: This course is self-paced, fully online.
- Time to Complete: All coursework must be completed within 16 weeks from the date of registration or before date of UAN expiration, 10/21/2025, whichever comes first. This course will no longer be eligible for CE credit after 10/21/2025.
The fully online, self-paced program is designed to equip the pharmacist with the knowledge necessary to implement pharmacogenomics into clinical practice in a variety of settings. Leading experts in the field of pharmacogenomics will provide educational content focusing on the following: background of pharmacogenomics, aspects of pharmacogenomic testing (laboratory considerations and interpretation of results), clinical implications of pharmacogenomics in multiple disease states including cardiology, oncology, pain management, and psychiatry, and adverse drug reactions (ADRs). Learners who complete the program and earn the certificate will be able to utilize pharmacogenomics resources, apply pharmacogenomics to clinical care, and implement pharmacogenomics in diverse clinical settings.
Module 1: Introduction to Pharmacogenomics
This content will provide the foundational knowledge needed to guide the learner through the certificate.
Module 2: Science of Pharmacogenomics
This module will define pharmacogenetics and pharmacogenomics and outline the benefits of genomic medicine. Content will focus specifically on pharmacogenomics of drug metabolism and drug transporters.
Module 3: Fundamentals of Clinical Pharmacogenomics and Pharmacogenomic Testing
This module will define the CPIC guidelines and explain how they can be used by clinicians to make specific prescribing decisions for patient care when genetic information is available. It will also review available evidence sources for pharmacogenomic recommendations and explain strategies for using the Pharmacogenomics Knowledgebase (PharmGKB) to assess the usefulness and practical applications of pharmacogenomic information in the clinical setting. Content will also review clinical laboratory and direct-to-consumer pharmacogenomic testing.
Module 4: Cardiology and Oncology
This module will discuss clinical implications of genetic variability in oncology pharmacotherapy and patient-specific, genetic, and other factors that inform drug therapy changes in oncology. It will also summarize clinical implications of genetic variability on cardiovascular drug response and explain factors influencing the clinical implementation of genotyping to help guide cardiovascular drug therapy.
Module 5: Pain Management, Psychiatry, and ADRs
This module will identify medications affected by multiple genes and summarize the clinical implications of genetic variability in pain management and psychiatry. Content will specifically focus on pain management, adverse drug reactions/hypersensitivity, and psychiatry pharmacogenetics.
Module 6: Clinical Implementation of Pharmacogenomics
This module will summarize how to develop a clinical pharmacogenomic service, manage testing and reimbursement for pharmacogenetic results, and design electronic and written documentation. Content will focus on clinical decision support, patient and provider education, and challenges and solutions for implementing pharmacogenomics in diverse practice settings.
At the completion of this activity, the participant will be able to:
- Describe the contribution of genetics to interindividual variability in drug metabolizing enzymes and predicting patient’s response to therapy.
- Apply information from pharmacogenomic resources, databases, and guidelines to clinical practice and patient case scenarios.
- Educate patients and providers in the utility and implications of pharmacogenomic testing and resulting information.
- Utilize pharmacogenomic information to develop treatment recommendations in certain disease states including cardiovascular, cancer, and psychiatric conditions.
- Create a plan to implement pharmacogenomic information and clinical decision support tools into electronic health records in various practice settings.
D. Max Smith, Pharm.D., BCPS
Clinical Pharmacogenomics Specialist at MedStar Health
Assistant Professor at Georgetown University Medical Center
Amanda Elchynski, Pharm.D., BCPS
Pharmacogenomics Clinical Coordinator at Arkansas Children’s Hospital
Jamie Wilkey, Pharm.D.
Founder, PGx Consulting Confidence Academy
Chief Executive Officer, Arches Health, LLC
Disclosure Statement: None of our speakers, reviewers, or planning committee members have disclosed any relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.
Schedule of Activities and Requirements for Successful Course Completion
To successfully pass this course the participant must complete the following:
- View all recorded lectures
- Complete all learning assessments
- Complete all case assignments
- Complete the course evaluation
All program content must be submitted and the participant must achieve a passing score of 70% or more on all course assignments to receive continuing education credit and a certificate of completion. Pharmacists are given 16 weeks from the date of registration (or until UAN expiration) to complete the course.
The Office of Continuing Pharmacy Education can mail you a printed certificate of completion for an additional $25.00. Contact us for more information.
Please review the resources below before registering for the course.
The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.